Leveraging the massive cash flow generated by its weight-loss drugs, Eli Lilly (LLY) is initiating the largest acquisition spree in the company’s history. Data shows that since the start of 2026, Eli Lilly has announced over $20 billion in acquisition and partnership deals, setting a new record for annual M&A spending, which includes subsequent milestone payments.
Analysts point out that the world’s most valuable pharmaceutical company by market capitalization is utilizing the “super cash flow” created by its weight-loss drug business to rapidly expand into new areas such as cancer, gene therapy, vaccines, and AI-driven drug development, in order to avoid repeating past mistakes of “blockbuster drug dependency.” In just the past few weeks, Eli Lilly has announced several major deals: an acquisition of sleep drug developer Centessa Pharmaceuticals (CNTA) for up to $7.8 billion, an acquisition of cancer drug developer Kelonia Therapeutics for up to $7 billion, and the acquisition of three vaccine development companies for up to $3.8 billion. Jake Van Naarden, head of Eli Lilly’s oncology and business development, revealed that the company’s team currently evaluates at least 10 potential M&A projects per week, but many multi-billion-dollar deals are still being rejected by target companies.
Currently, Eli Lilly’s weight-loss drug Zepbound and diabetes drug Mounjaro still have about 10 years of patent protection remaining, but company executives clearly do not want to fall back into the predicament of “growth stalling after the patent expiration of star drugs.” Eli Lilly experienced a decade-long growth slump in the 2000s following the patent expiry of its antidepressant Prozac. Now, with a market capitalization approaching $1 trillion, Eli Lilly is under immense pressure from market expectations for its future growth and must proactively plan for the next long-term growth cycle. Therefore, the current M&A logic is not simply focused on weight-loss drugs, but rather on massively expanding future technology platforms such as cancer treatment, gene therapy, immunology, neuroscience, and AI-driven drug discovery.
Notably, Eli Lilly is making significant bets on cutting-edge areas where some other pharmaceutical companies remain cautious. Despite high research and development costs and uncertain commercialization pathways, Eli Lilly is still doubling down on gene therapy against the trend. In January of this year, the company signed an $1.1 billion collaboration agreement with German biotech firm Seamless Therapeutics to develop gene therapies for hearing loss. At the same time, Eli Lilly is also aggressively expanding in the AI drug development space: in April of this year, it announced a collaboration with AI biotech company Profluent worth up to $2.25 billion; and in March, it signed a collaboration with Insilico Medicine worth up to $2.75 billion.
Market observers believe Eli Lilly’s current strategic core is very clear: to use the massive profits from weight-loss drugs to rapidly complete the construction of its next product pipeline before the upcoming patent expiration cycle arrives. The competition among major global pharmaceutical companies is no longer just about single drugs; it increasingly resembles an arms race centered on “future technology platforms.” Eli Lilly is clearly trying to seize a leading position in this race.
